Lurasidone CINFA 37 mg film-coated tablets EFG

Package leaflet: Information for the user

Introduction

Package leaflet: information for the patient

Lurasidona cinfa 18.5 mg film-coated tablets EFG

Lurasidona cinfa 37 mg film-coated tablets EFG

Lurasidona cinfa 74 mg film-coated tablets EFG

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to other people, even if they have the same symptoms as you, because it may harm them.
• If you experience any adverse effects, talk to your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Contents of the leaflet

1. What Lurasidona cinfa is and what it is used for
2. What you need to know before taking Lurasidona cinfa
3. How to take Lurasidona cinfa
4. Possible side effects
5. How to store Lurasidona cinfa
6. Contents of the pack and other information

1. What Lurasidona cinfa is and what it is used for

Lurasidona cinfa contains the active substance lurasidona and belongs to a group of medicines called antipsychotics. It is used to treat the symptoms of schizophrenia in adults (18 years of age and older) and adolescents aged 13 to 17 years. Lurasidona works by blocking brain receptors that are acted upon by the substances dopamine and serotonin. Dopamine and serotonin are neurotransmitters (substances that allow nerve cells to communicate with each other) involved in the symptoms of schizophrenia. By blocking these receptors, lurasidona helps normalize brain activity, thereby reducing the symptoms of schizophrenia.

Schizophrenia is a disorder characterized by symptoms such as hearing, seeing, or feeling things that do not exist, having false beliefs, excessive suspicion, social withdrawal, incoherent speech and behavior, and lack of emotion. People with this disorder may feel depressed, distressed, guilty, or tense. This medicine is used to improve their symptoms of schizophrenia.

2. What you need to know before starting to take Lurasidona cinfa

Do not take Lurasidona cinfa

• if you are allergic to lurasidone or to any of the other ingredients of this medicine (listed in section 6)
• if you are taking medicines that may affect the concentration of lurasidone in the blood, such as:
  • antifungal medicines such as itraconazole, ketoconazole (except in shampoo), posaconazole, or voriconazole
  • medicines for infections, such as the antibiotic clarithromycin or telithromycin
  • medicines for HIV infection such as cobicistat, indinavir, nelfinavir, ritonavir, and saquinavir
  • medicines for chronic hepatitis such as boceprevir and telaprevir
  • nefazodone, a medicine for depression
  • rifampicin, a medicine for tuberculosis
  • medicines for seizures such as carbamazepine, phenobarbital, and phenytoin
  • St. John’s wort (Hypericum perforatum), a herbal remedy used to treat depression.

Warnings and precautions

The full effect of this medicine may take several days or even weeks to appear. Consult your doctor if you have any doubts about this medicine.

Consult your doctor or pharmacist before taking lurasidona or during treatment, especially if:

• you have suicidal thoughts or behaviors
• you suffer from Parkinson’s disease or dementia
• you have ever been diagnosed with a condition whose symptoms include high fever and muscle stiffness (also known as neuroleptic malignant syndrome), or have previously experienced stiffness, tremors, or movement problems (extrapyramidal symptoms), or abnormal movements of the tongue or face (tardive dyskinesia). You should be aware that these conditions may be caused by this medicine
• you have heart disease or are being treated for a heart condition that makes you prone to low blood pressure, or have a family history of irregular heartbeats (including QT prolongation)
• you have a history of seizures or epilepsy
• you have a history of blood clots, or another member of your family has a history of blood clots, as antipsychotic medicines have been associated with blood clot formation
• breast enlargement in men (gynecomastia), milky discharge from the nipples (galactorrhea), absence of menstruation (amenorrhea), or erectile dysfunction
• you have diabetes or are prone to it
• you have reduced kidney function
• you have reduced liver function
• you gain weight
• your blood pressure drops when you stand up, which may cause fainting
• you are dependent on opioids (treated with buprenorphine) or have severe pain (treated with opioids), or suffer from depression or other conditions treated with antidepressants. Using these medicines together with lurasidone may cause serotonin syndrome, a potentially life-threatening condition (see “Other medicines and Lurasidona cinfa”).

If any of these conditions apply to you, consult your doctor, as they may wish to adjust your dose, monitor you more closely, or discontinue treatment with lurasidone.

Children and adolescents

Do not administer to children under 13 years of age.

Other medicines and Lurasidona cinfa

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines. This is especially important if you are taking:

• any medicine that also acts on the brain, as their effects could add negatively to those of lurasidone in your brain
• medicines that lower blood pressure, as this medicine may also reduce blood pressure
• medicines for Parkinson’s disease and restless legs syndrome (e.g., levodopa), as this medicine may reduce their effectiveness
• medicines containing ergot alkaloid derivatives (used to treat migraines), and other medicines such as terfenadine and astemizole (used to treat hay fever and other allergic conditions), cisapride (used to treat digestive problems), pimozide (used to treat psychiatric illnesses), quinidine (used to treat heart conditions), bepridil (used to treat chest pain)
• medicines containing buprenorphine (used to treat opioid dependence) or opioids (used to treat severe pain), or antidepressants such as moclobemide, tranylcypromine, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, amitriptyline, doxepin, or trimipramine. These medicines may interact with lurasidone and you may experience symptoms such as involuntary and rhythmic muscle contractions, including muscles controlling eye movement, agitation, hallucinations, coma, excessive sweating, tremor, exaggerated reflexes, increased muscle tension, body temperature above 38°C. If you experience these symptoms, consult your doctor.

Inform your doctor if you are taking any of these medicines, as your dose of that medicine may need to be changed during treatment with lurasidone.

The following medicines may increase the concentration of lurasidone in your blood:

• diltiazem (to treat hypertension)
• erythromycin (to treat infections)
• fluconazole (to treat fungal infections)
• verapamil (to treat hypertension or chest pain).

The following medicines may decrease the concentration of lurasidone in your blood:

• amprenavir, efavirenz, etravirine (to treat HIV infection)
• aprepitant (to treat nausea and vomiting)
• armodafinil, modafinil (to treat sleepiness)
• bosentan (to treat high blood pressure or finger ulcers)
• nafcillin (to treat infections)
• prednisone (to treat inflammatory diseases)
• rufinamide (to treat seizures).

Inform your doctor if you are taking any of these medicines, as your dose of lurasidone may need to be changed.

Taking Lurasidona cinfa with food, drinks, and alcohol

Alcohol consumption should be avoided when taking this medicine, as it will have an additive negative effect.

Do not drink grapefruit juice while taking this medicine. Grapefruit may affect the action of this medicine.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

You should not take this medicine during pregnancy unless your doctor has specifically advised you to do so.

If your doctor decides that the potential benefit of treatment during pregnancy justifies the potential risk to the unborn child, your doctor will closely monitor your baby after birth. This is because the following symptoms may occur in newborns whose mothers have used lurasidone during the third trimester (last three months) of pregnancy:

• tremors, muscle stiffness or weakness, drowsiness, agitation, breathing difficulties, and feeding problems.

If your baby develops any of these symptoms, you should consult your doctor.

It is unknown whether lurasidone passes into breast milk. Inform your doctor if you are breastfeeding or intend to breastfeed.

Driving and using machines

During treatment with this medicine, drowsiness, dizziness, and vision problems may occur (see section 4, Possible side effects). Do not drive, ride a bicycle, or operate tools or machinery until you know that this medicine does not affect you negatively.

Lurasidona cinfa contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per tablet; i.e., essentially “sodium-free”.

3. How to take Lurasidona cinfa

Follow exactly the instructions for use of this medicine as given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Your dose will be determined by your doctor and may depend on:

• how you respond to a dose
• whether you are taking other medicines (see section 2, Other medicines and Lurasidona cinfa)
• whether you have kidney or liver problems.

Adults (18 years of age or older)

The recommended starting dose is 37 mg once daily.

Your doctor may increase or decrease your dose within the range of 18.5 mg to 148 mg once daily. The maximum dose must not exceed 148 mg once daily.

Adolescents aged 13 to 17 years

The recommended starting dose is 37 mg of lurasidone once daily.

Your doctor may increase or decrease the dose within the range of 37 mg to 74 mg once daily. The maximum daily dose must not exceed 74 mg.

How to take Lurasidona cinfa

Swallow the tablet whole with water, to mask its bitter taste. You should take the dose regularly every day at the same time, to make it easier to remember. You must take this medicine with food or immediately after eating, as this helps your body absorb the medicine and allows it to work better.

If you take more Lurasidona cinfa than you should

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service at 91 562 04 20, indicating the medicine and the amount ingested.

You may experience drowsiness, fatigue, abnormal body movements, difficulty standing and walking, dizziness due to low blood pressure, and abnormal heartbeats.

If you forget to take Lurasidona cinfa

Do not take a double dose to make up for missed doses. If you forget to take a dose, take the next dose on the day following the missed dose. If you miss two or more doses, consult your doctor.

If you stop taking Lurasidona cinfa

If you stop taking this medicine, you will lose its effects. You should not stop taking the medicine unless instructed by your doctor, as symptoms may return.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

Seek immediate medical attention if you notice any of the following symptoms:

• a severe allergic reaction including fever, swelling of the mouth, face, lips or tongue, difficulty breathing, itching, skin rash and sometimes a drop in blood pressure (hypersensitivity). These reactions are common (may affect up to 1 in 10 people)
• severe blistering rash affecting the skin, mouth, eyes and genitals (Stevens-Johnson syndrome). This reaction has an unknown frequency
• fever, sweating, muscle stiffness and decreased level of consciousness. These could be symptoms of a condition known as neuroleptic malignant syndrome. These reactions are rare (may affect up to 1 in 1,000 people)
• blood clots in the veins, especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through the blood vessels to the lungs and cause chest pain and difficulty breathing. If you notice any of these symptoms, seek medical attention immediately.

The following adverse effects may also occur in adults:

Very common (may affect more than 1 in 10 people):

• feeling restless and unable to sit still
• nausea (feeling sick)
• insomnia.

Common (may affect up to 1 in 10 people):

• Parkinsonism: this medical term describes a number of symptoms, including increased salivary secretion or very moist mouth, drooling, spasms when bending limbs, slow, reduced or difficult body movements, expressionless face, muscle tension, neck stiffness, muscle rigidity, short, shuffling and hurried steps, lack of normal arm movements when walking, persistent blinking when tapping the forehead (abnormal reflex)
• speech problems, unusual muscle movements; a group of symptoms known as extrapyramidal symptoms (EPS), which usually include unnecessary involuntary muscle movements
• fast heart rate
• increased blood pressure
• dizziness
• muscle spasms and stiffness
• vomiting
• diarrhoea
• back pain
• rash and itching
• indigestion
• dry mouth or excess saliva
• abdominal pain
• drowsiness, tiredness, restlessness and anxiety
• weight gain
• increased levels of creatine phosphokinase (an enzyme in muscles) in blood tests
• increased levels of creatinine (a marker of kidney function) seen in blood tests
• decreased appetite.

Uncommon (may affect up to 1 in 100 people):

• slow and difficult speech
• nightmares
• difficulty swallowing
• irritation of the stomach lining
• sudden feeling of anxiety
• seizures
• chest pain
• muscle pain
• temporary loss of consciousness
• sensation of spinning (vertigo)
• abnormal nerve impulses in the heart
• low heart rate
• joint pain
• difficulty walking
• rigid posture
• increases in blood levels of prolactin and glucose (blood sugar) or certain liver enzymes seen in blood tests
• drop in blood pressure upon standing, which may cause fainting
• common cold
• hot flushes
• blurred vision
• sweating
• pain when urinating
• involuntary movements of the mouth, tongue and limbs (tardive dyskinesia)
• low levels of sodium in the blood, which may cause tiredness and confusion, muscle spasms, seizures and coma (hyponatremia)
• lack of energy (lethargy)
• gas (flatulence)
• neck pain
• erection problems
• painful or absent menstrual periods.

Rare (may affect up to 1 in 1,000 people):

• Rhabdomyolysis, which is the breakdown of muscle fibres, leading to the release of muscle fibre contents (myoglobin) into the bloodstream, causing muscle pain, nausea, confusion, abnormal heart rate and rhythm, and possibly dark urine
• increased eosinophils (a type of white blood cell)
• swelling beneath the skin (angioedema)
• deliberate self-injury
• stroke
• kidney failure
• reduced number of red blood cells (which carry oxygen throughout the body)
• breast pain, milk discharge from the breasts
• sudden death.

Frequency unknown (cannot be estimated from available data):

• reduced number of a subgroup of white blood cells (neutrophils)
• sleep disorder
• newborns may show the following: restlessness, increased or decreased muscle tone, tremor, drowsiness, breathing or feeding difficulties
• abnormal enlargement of the breast.

In elderly patients with dementia, a small increase in the number of deaths has been reported in patients taking antipsychotic medicines compared to those not taking them.

The following adverse effects may occur in adolescents:

Very common (may affect more than 1 in 10 people):

• feeling restless and unable to sit still
• headache
• drowsiness
• nausea.

Common (may affect up to 1 in 10 people):

• reduced or increased appetite
• abnormal dreams
• difficulty sleeping, tension, restlessness, anxiety and irritability
• physical weakness, tiredness
• depression
• psychotic disorder: a medical term describing various mental illnesses causing abnormal thoughts and perceptions; people with psychosis lose touch with reality
• symptoms of schizophrenia
• difficulty concentrating
• sensation of spinning (vertigo)
• abnormal involuntary movements (dyskinesia)
• abnormal muscle tone, including torticollis and involuntary upward deviation of the eyes
• Parkinsonism: this medical term describes numerous symptoms, including increased salivary secretion or very moist mouth, drooling, spasms when bending limbs, slow, reduced or difficult body movements, expressionless face, muscle tension, neck stiffness, muscle rigidity, short, shuffling and hurried steps, lack of normal arm movements when walking, persistent blinking when tapping the forehead (abnormal reflex)
• rapid heartbeat
• difficulty emptying the bowels (constipation)
• dry mouth or excess saliva
• vomiting
• sweating
• muscle stiffness
• erection problems
• increased levels of creatine phosphokinase (a muscle enzyme) in blood tests
• increased levels of prolactin (a hormone) in blood, seen in blood tests
• weight gain or weight loss.

Uncommon (may affect up to 1 in 100 people):

• hypersensitivity
• common cold, throat and nasal infection
• decreased thyroid activity, thyroid inflammation
• aggressive behaviour, impulsive behaviour
• apathy
• confusion
• depressed mood
• separation from normal mental processes (dissociation)
• hallucination (auditory or visual)
• homicidal thoughts
• difficulty sleeping
• increased or decreased sex drive
• lack of energy
• altered mental state
• obsessive thoughts
• sudden, overwhelming feeling of anxiety (panic attack)
• performing unnecessary involuntary movements (psychomotor hyperactivity)
• hyperactivity of body muscles (hyperkinesia), inability to rest (restlessness)
• uncontrollable urge to move the legs (restless legs syndrome), uncontrollable movements of the mouth, tongue and limbs (tardive dyskinesia)
• sleep disorders
• deliberate suicidal thoughts
• abnormal thoughts
• instability (sensation of spinning)
• altered sense of taste
• memory impairment
• abnormal skin sensations (paresthesia)
• sensation of a tight band around the head (tension headache), migraine
• difficulty focusing the eyes, blurred vision
• increased sensitivity to sound
• palpitations, heart rhythm disturbances
• drop in blood pressure upon standing, which may cause fainting
• increased blood pressure
• abdominal pain or discomfort
• partial or complete absence of saliva secretion
• diarrhoea
• indigestion
• dry lips
• toothache
• partial or complete hair loss, abnormal hair growth
• rash, hives
• muscle spasms and stiffness, muscle pain
• joint pain, pain in arms and legs, jaw pain
• presence of bilirubin in urine, presence of protein in urine, a marker of kidney function
• pain or difficulty urinating, frequent urination, kidney disorder
• sexual dysfunction
• difficulty with ejaculation
• abnormal enlargement of the breasts, breast pain, milk discharge from the breasts
• absent or irregular menstruation
• uncontrollable noises and movements (Tourette's disorder)
• chills
• difficulty walking
• malaise
• chest pain
• fever
• intentional overdose
• effects on thyroid function seen in blood tests, increased blood cholesterol, increased blood triglycerides, decreased high-density lipoproteins, decreased low-density lipoproteins, seen in blood tests
• increased blood glucose (blood sugar), increased blood insulin, increased levels of certain liver enzymes (a marker of liver function), seen in blood tests
• increased or decreased blood testosterone, increased thyroid-stimulating hormone in blood, seen in blood tests
• electrocardiogram abnormalities
• decreased haemoglobin, reduced number of white blood cells (which fight infection), seen in blood tests.

Reporting of adverse effects

If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Lurasidone cinfa

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the packaging and blister after "EXP". The expiry date refers to the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines must not be disposed of via wastewater or household waste. Dispose of unused medicines and their containers at the SIGRE point located at your pharmacy. Ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

6. Package contents and other information

Composition of Lurasidona cinfa

• The active substance is lurasidone.

Each 18.5 mg tablet contains lurasidone hydrochloride equivalent to 18.6 mg of lurasidone.

Each 37 mg tablet contains lurasidone hydrochloride equivalent to 37.2 mg of lurasidone.

Each 74 mg tablet contains lurasidone hydrochloride equivalent to 74.5 mg of lurasidone.

• The other components are:
  • Core: microcrystalline cellulose, mannitol (E-421), hypromellose, sodium croscarmellose and magnesium stearate.
  • Coating: hypromellose, titanium dioxide (E-171), macrogol, yellow iron oxide (E-172) (present in the 74 mg tablets) and indigo carmine (E-132) (present in the 74 mg tablets).

Appearance of the product and contents of the pack

Lurasidona cinfa 18.5 mg film-coated tablets EFG

Film-coated round tablets, white or almost white, engraved with "LL" on one side and smooth on the other, with a diameter of 6.1 mm.

Lurasidona cinfa 37 mg film-coated tablets EFG

Film-coated round tablets, white or almost white, engraved with "LI" on one side and smooth on the other, with a diameter of 8.1 mm.

Lurasidona cinfa 74 mg film-coated tablets EFG

Film-coated oval tablets, pale green to green, engraved with "LH" on one side and smooth on the other, measuring 12.1 mm x 7.1 mm.

Available in pack sizes containing 28 tablets in single-dose OPA/Al/PVC//Al perforated blisters.

Marketing Authorization Holder

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10. Polígono Industrial Areta

31620 Huarte (Navarra) – Spain

Manufacturer

ELPEN Pharmaceutical Co Inc

Marathonos Ave. 95, Pikermi Attiki,

19009, Greece

or

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10. Polígono Industrial Areta

31620 Huarte (Navarra) – Spain

Date of the most recent revision of this summary: September 2024

Detailed information on this medicine is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)

You can access detailed and up-to-date information about this medicine by scanning with your mobile phone (smartphone) the QR code included in the package leaflet and packaging. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/89813/P_89813.html

QR code: https://cima.aemps.es/cima/dochtml/p/89813/P_89813.html